Quantitative measurement of PTEN loss improves risk assessment in prostate cancer (2019)
- Authors:
- USP affiliated authors: REIS, RODOLFO BORGES DOS - FMRP ; SQUIRE, JEREMY ANDREW - FMRP
- Unidade: FMRP
- DOI: 10.1097/01.JU.0000555707.15264.f6
- Subjects: NEOPLASIAS; PRÓSTATA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2019
- Source:
- Título: The Journal of Urology
- ISSN: 0022-5347
- Volume/Número/Paginação/Ano: v. 201, suppl. 4, p. e403, res. MP28-02, 2019
- Conference titles: Annual Meeting American Urological Association -AUA
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
JAMASPISHVILI, Tamara et al. Quantitative measurement of PTEN loss improves risk assessment in prostate cancer. The Journal of Urology. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1097/01.JU.0000555707.15264.f6. Acesso em: 16 fev. 2026. , 2019 -
APA
Jamaspishvili, T., Patel, P., Yi Niu, D., Vidotto, T., Caven, I., Livergant, R., et al. (2019). Quantitative measurement of PTEN loss improves risk assessment in prostate cancer. The Journal of Urology. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1097/01.JU.0000555707.15264.f6 -
NLM
Jamaspishvili T, Patel P, Yi Niu D, Vidotto T, Caven I, Livergant R, Fu W, Ouellet V, Picanço C, Koti M, How N, Saad F, Mes-Masson A-M, Lotan T, Squire JA, Peng Y, Berman D, Reis RB dos. Quantitative measurement of PTEN loss improves risk assessment in prostate cancer [Internet]. The Journal of Urology. 2019 ; 201 e403.[citado 2026 fev. 16 ] Available from: https://doi.org/10.1097/01.JU.0000555707.15264.f6 -
Vancouver
Jamaspishvili T, Patel P, Yi Niu D, Vidotto T, Caven I, Livergant R, Fu W, Ouellet V, Picanço C, Koti M, How N, Saad F, Mes-Masson A-M, Lotan T, Squire JA, Peng Y, Berman D, Reis RB dos. Quantitative measurement of PTEN loss improves risk assessment in prostate cancer [Internet]. The Journal of Urology. 2019 ; 201 e403.[citado 2026 fev. 16 ] Available from: https://doi.org/10.1097/01.JU.0000555707.15264.f6 - Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN)
- Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer
- Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment
- Emerging role of PTEN loss in evasion of the immune response to tumours
- TCGA analysis identifies distinct genomic features of oncogenic progression and outcome associated with hemizygous PTEN loss tumors
- Analysis of the impact of ZEB1 expression on pathway enrichment and immune cell abundance in prostate cancer
- A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer
- Extracellular vesicles: evolving factors in stem cell biology
- Quantitative assessment of PTEN loss (qPTEN) is strongly associated with biochemical recurrence and may improve treatment decisions after surgery
- In silico shows that PTEN loss and AR overexpression are associated with increased CD8+ T-cell and Treg density and earlier disease recurrence in prostate cancer
Informações sobre o DOI: 10.1097/01.JU.0000555707.15264.f6 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
